• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Mid-Cycle Review Memorandum(2), April 16, 2009 - Anascorp

 

  
DATE

April 16, 2009
 

FROM
Robert Wesley, Bioresearch Monitoring Branch, HFM-664
Division of Inspections and Surveillance
Office of Compliance and Biologics Quality

 

THROUGH


Patricia Holobaugh, BIMO Branch Chief, HFM-664
TO

Debbie Cordaro, HFM-380, RPM

SUBJECT
Mid-Cycle Review Memo
Sponsor: Bioclon
Product: Scorpion Antivenin
BLA/ STN 125335/0

 
INTERIM SUMMARY STATEMENT
 
-------------------------------------------------------------------------------------------------------------------------------------------Information withheld per the Privacy Act------------.
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Information withheld per the Privacy Act--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------.
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Information withheld per the Privacy Act-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------.
 
-------------------------------Information withheld per the Privacy Act-----------------------------------------------------------------------------------------------------------------------------------.